Revenue fell 9 per cent to $12.69 billion, partly hurt by intense competition for its pain treatment Lyrica that lost patent protection last year.
Excluding items, it earned 55 cents per share, missing the average analyst estimate of 58 cents per share. Net loss attributable to Pfizer narrowed to $337 million, or 6 cents per share, in the quarter, from $394 million, or 7 cents per share, a year earlier.
globebusiness Now watch breast cancer stats climb. Big pharma create illnesses to drive sales.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: